As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Envoy Medical, Inc. The largest reported stake is Glen A. Taylor's, at 84.8%. 8 filings are on record since August 21, 2025 (Schedule 13D/A, February 17, 2026).
Sell to companies like Envoy Medical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Alta Partners LLC · Sole voting: 2,054,011 · Shared voting: 0 · Sole dispositive: 2,054,011 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-09-14
- · Holder: Nantahala Capital Management, LLC · Percent: 9.99% · SCHEDULE 13G
- · Holder: Bleichroeder LP · Percent: 9.99% · SCHEDULE 13G
- · Holder: Ayrton Capital LLC · Percent: 3.1% · SCHEDULE 13G/A
- · Holder: Glen A. Taylor · Percent: 84.8% · SCHEDULE 13D/A
Envoy Medical, Inc. has 8 Schedule 13D or 13G filings on record since 2025-08-21. 3 holders' latest filing reports 5% or more of class a common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 84.8% | 68,909,614 | SCHEDULE 13D/A, 2026-02-17 | 2026-02-12 | |
| Bleichroeder LP | 9.99% | 7,839,000 | SCHEDULE 13G, 2026-05-14 | 2026-03-31 |
| Nantahala Capital Management, LLC | 9.99% | 7,683,798 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Ayrton Capital LLC | 3.1% | 2,457,963 | SCHEDULE 13G/A, 2026-05-11 | 2026-03-31 |
| Alta Partners LLC | 2.6% | 2,054,011 | SCHEDULE 13G/A, 2026-09-14 | 2026-08-10 |
Holding shares or following this stake? See who's behind Envoy Medical, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Envoy Medical, Inc. and the records around it.
Envoy Medical, Inc. elsewhere on the record
- Leadership changes Aug 2026
- IPO filing Feb 2026
- Who owns it
Companies that share a holder
- Bleichroeder LP also filed stake reports on 16 other companies: MDxHealth SA (Oct 2026), Identiv, Inc. (INVE) (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026)
- Alta Partners LLC also filed stake reports on 26 other companies: Robin Energy Ltd. (Oct 2026), Huachen AI Parking Management Technology Holding Co., Ltd (Oct 2026), C3is Inc. (Oct 2026)
- Ayrton Capital LLC also filed stake reports on 31 other companies: Bluejay Diagnostics, Inc. (Aug 2026), BTC Digital Ltd. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026)
Watch Envoy Medical, Inc.
Get an email when Envoy Medical, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Envoy Medical, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Envoy Medical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Envoy Medical, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Alta Partners LLC | 2,054,011 | 0 | 2,054,011 | 0 | SCHEDULE 13G/A, 2026-09-14 |
The latest filing identifies Envoy Medical, Inc. by CUSIP 29415V117 and gives its principal executive office as 4875 WHITE BEAR PARKWAY, WHITE BEAR LAKE, MN 55110 (SCHEDULE 13G/A, 2026-09-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-21 | Alta Partners LLC | 8.3% | SCHEDULE 13G |
| 2025-12-08 | Glen A. Taylor | 44.2% | SCHEDULE 13D |
| 2026-02-11 | Ayrton Capital LLC | 7.87% | SCHEDULE 13G |
| 2026-02-17 | Glen A. Taylor | 84.8% | SCHEDULE 13D/A |
| 2026-05-11 | Ayrton Capital LLC | 3.1% | SCHEDULE 13G/A |
| 2026-05-14 | Bleichroeder LP | 9.99% | SCHEDULE 13G |
| 2026-05-15 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G |
| 2026-09-14 | Alta Partners LLC | 2.6% | SCHEDULE 13G/A |
Questions about who owns Envoy Medical, Inc.
Who owns Envoy Medical, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Envoy Medical, Inc.: Glen A. Taylor (84.8%, Schedule 13D/A, filed 2026-02-17), Bleichroeder LP (9.99%, Schedule 13G, filed 2026-05-14) and Nantahala Capital Management, LLC (9.99%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Envoy Medical, Inc.?
By the share each holder's latest filing reports, the largest holders of Envoy Medical, Inc. on this page are Glen A. Taylor (84.8%), Bleichroeder LP (9.99%) and Nantahala Capital Management, LLC (9.99%).
When did Glen A. Taylor buy into Envoy Medical, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Glen A. Taylor on this page is the Schedule 13D, filed 2025-12-08, reporting 44.2%; its latest, Schedule 13D/A filed 2026-02-17, reports 84.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Envoy Medical, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 27, 2026 | Leadership change: Robert Potashnick appointed, Chief Accounting Officer | — | Leadership changes | Source |
| April 21, 2026 | Leadership change: Charles S. McKhann appointed, Director | — | Leadership changes | Source |
| February 12, 2026 | IPO filing, Form 424B4 | $0.4 a share | IPO filings | Source |
| February 12, 2026 | IPO filing, Form 424B4 | $0.4 a share | IPO filings | Source |
| February 10, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| February 6, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| December 18, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| December 1, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| October 17, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Envoy Medical, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.